Imaging response predictors following drug eluting beads chemoembolization in the neoadjuvant liver transplant treatment of hepatocellular carcinoma

Table 2 Pre procedure laboratory characteristics according to objective response - target lesion response (mRECIST)

Variable	NR (n = 44)	RE (n = 141)	Total (n = 185)	P value
Hb (g/dL)	12.9 ± 2.5	12.9 ± 2	12.9 ± 2.1	0.6671
Ht (%)	37.1 ± 6.7	37.4 ± 5.6	37.3 ± 5.9	0.8621
Creatinine (mg/dL)	0.95 ± 0.81	0.92 ± 0.86	0.93 ± 0.84	0.4591
Albumin (g/dL)	3.43 ± 0.53	3.34 ± 0.55	3.37 ± 0.54	0.5751
Alphafetoprotein (UI/mL)	200.3 ± 463	435.1 ± 2307.2	379.3 ± 2027.7	0.3201
Direct bilirubin (mg/dL)	0.73 ± 0.49	0.65 ± 0.41	0.67 ± 0.43	0.6481
Indirec bilirubina (mg/dL)	1.43 ± 0.87	1.14 ± 0.71	1.21 ± 0.76	0.0501
Total bilirubin (mg/dL)	1.9 ± 1.11	1.78 ± 0.89	1.81 ± 0.94	0.8421
INR	1.31 ± 0.19	1.31 ± 0.21	1.31 ± 0.2	0.7781
Platelets (x 103/mm3)	85 ± 42.9	91.7 ± 54.8	90.1 ± 52.1	0.8101
AST (U/L)	87 ± 68.1	84.4 ± 59	85.1 ± 61.3	0.8421
ALT (U/L)	71.4 ± 52.4	71.5 ± 49.7	71.5 ± 50.2	0.8251

¹Student's t-test. NR: Non-responder; RE: Respondent; Hb: Hemoglobin; Ht: Hematocrit; INR: International normalized ratio; AST: Glutamic-oxalacetic transamisnase; ALT: Glutamic-pyruvic transaminase.